Attacking IBD Through a Novel Pathway episode artwork

EPISODE · Jan 17, 2019 · 19 MIN

Attacking IBD Through a Novel Pathway

from The Bio Report · host Levine Media Group

Current therapies for autoimmune diseases represent a $100 billion market, but available drugs often provide limited benefits to patients or cause problematic side effects. Landos Biopharma is targeting the area of autoimmune diseases with an initial focus on inflammatory bowel disease by pursuing therapies that target a novel pathway. We spoke to Landos founder and CEO Josep Bassaganya-Riera, about IBD, why new therapies are needed, and the approach Landos is taking.

Current therapies for autoimmune diseases represent a $100 billion market, but available drugs often provide limited benefits to patients or cause problematic side effects. Landos Biopharma is targeting the area of autoimmune diseases with an initial focus on inflammatory bowel disease by pursuing therapies that target a novel pathway. We spoke to Landos founder and CEO Josep Bassaganya-Riera, about IBD, why new therapies are needed, and the approach Landos is taking.

NOW PLAYING

Attacking IBD Through a Novel Pathway

0:00 19:36

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 19 minutes long.

When was this The Bio Report episode published?

This episode was published on January 17, 2019.

What is this episode about?

Current therapies for autoimmune diseases represent a $100 billion market, but available drugs often provide limited benefits to patients or cause problematic side effects. Landos Biopharma is targeting the area of autoimmune diseases with an...

Can I download this The Bio Report episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!